Asset Details
Do you wish to reserve the book?
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
Do you wish to request the book?
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia
2011
Overview
This study investigates the differential gene expression profile of JAK2
V617F
-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways:
MAPK
,
AKT
, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2
V617F
-positive MPN patients without response to HU treatment, with overexpression of
JAK2
,
MAPK14
,
PIK3CA
, and
SFK
genes.
Publisher
Springer-Verlag,Springer Nature B.V,Springer Verlag
Subject
/ Aged
/ Female
/ Gene Expression Regulation - drug effects
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ Hydroxyurea - therapeutic use
/ Male
/ Medicine
/ Oncology
/ Polycythemia Vera - drug therapy
/ Polycythemia Vera - genetics
/ Signal Transduction - drug effects
/ Signal Transduction - genetics
/ src-Family Kinases - genetics
/ Thrombocythemia, Essential - drug therapy
/ Thrombocythemia, Essential - genetics
/ Transcription Factors - drug effects
